

Daniel E Weiner

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6594792/publications.pdf>

Version: 2024-02-01

232
papers

15,613
citations

22099

59
h-index

19690

117
g-index

239
all docs

239
docs citations

239
times ranked

17853
citing authors

#	ARTICLE	IF	CITATIONS
1	End-stage renal disease and metalworking fluid exposure. <i>Occupational and Environmental Medicine</i> , 2022, 79, 24-31.	1.3	3
2	Mobility in Older Adults Receiving Maintenance Hemodialysis: A Qualitative Study. <i>American Journal of Kidney Diseases</i> , 2022, 79, 539-548.e1.	2.1	6
3	Prevention and management of cardiovascular disease in kidney disease and kidney failure. , 2022, , 207-223.		0
4	Seroresponse to SARS-CoV-2 Vaccines Among Maintenance Dialysis Patients. <i>American Journal of Kidney Diseases</i> , 2022, 79, 307-310.	2.1	22
5	Vitamin K status, all-cause mortality, and cardiovascular disease in adults with chronic kidney disease: the Chronic Renal Insufficiency Cohort. <i>American Journal of Clinical Nutrition</i> , 2022, 115, 941-948.	2.2	9
6	Kidney Recovery and Death in Critically Ill Patients With COVID-19–Associated Acute Kidney Injury Treated With Dialysis: The STOP-COVID Cohort Study. <i>American Journal of Kidney Diseases</i> , 2022, 79, 404-416.e1.	2.1	23
7	Seroresponse to SARS-CoV-2 Vaccines among Maintenance Dialysis Patients over 6 Months. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2022, 17, 403-413.	2.2	43
8	Seroresponse to Inactivated and Recombinant Influenza Vaccines Among Maintenance Hemodialysis Patients. <i>American Journal of Kidney Diseases</i> , 2022, 80, 309-318.	2.1	5
9	Association of Intensive vs Standard Blood Pressure Control With Cerebral Blood Flow. <i>JAMA Neurology</i> , 2022, 79, 380.	4.5	26
10	Shared Decision Making Among Older Adults With Advanced CKD. <i>American Journal of Kidney Diseases</i> , 2022, 80, 599-609.	2.1	15
11	Seroresponse to Third Doses of SARS-CoV-2 Vaccine Among Patients Receiving Maintenance Dialysis. <i>American Journal of Kidney Diseases</i> , 2022, 80, 151-153.	2.1	8
12	Treating Early-Stage CKD With New Medication Therapies: Results of a CKD Patient Survey Informing the 2020 NKF-FDA Scientific Workshop on Clinical Trial Considerations for Developing Treatments for Early Stages of Common, Chronic Kidney Diseases. <i>Kidney Medicine</i> , 2022, 4, 100442.	1.0	5
13	The Relationship of Kidney Tubule Biomarkers with Brain Imaging in CKD Patients in SPRINT. <i>Kidney360</i> , 2022, 3, 337-340.	0.9	1
14	Value-Based Care in Chronic Kidney Disease. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2022, 17, 14-16.	2.2	2
15	Economic evaluation of expanded hemodialysis with the Theranova 400 dialyzer: A post hoc evaluation of a randomized clinical trial in the United States. <i>Hemodialysis International</i> , 2022, 26, 449-455.	0.4	4
16	Vitamin K Status and Cognitive Function in Adults with Chronic Kidney Disease: The Chronic Renal Insufficiency Cohort. <i>Current Developments in Nutrition</i> , 2022, 6, nza111.	0.1	4
17	Utilizing the Probation Office as an Opportunity to Screen for Cardiometabolic Outcomes: A Feasibility Study. <i>Journal of Correctional Health Care</i> , 2022, 28, 274-282.	0.2	2
18	Treatment Decision Making for Older Kidney Patients during COVID-19. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2022, 17, 957-965.	2.2	9

#	ARTICLE	IF	CITATIONS
19	Advance Care Planning in Older Adults with CKD: Patient, Care Partner, and Clinician Perspectives. Journal of the American Society of Nephrology: JASN, 2021, 32, 1527-1535.	3.0	30
20	Patient Education for Kidney Failure Treatment: A Mixed-Methods Study. American Journal of Kidney Diseases, 2021, 78, 690-699.	2.1	19
21	COVID-19 Among US Dialysis Patients: Risk Factors and Outcomes From a National Dialysis Provider. American Journal of Kidney Diseases, 2021, 77, 748-756.e1.	2.1	181
22	Dysuria, heat stress, and muscle injury among Nicaraguan sugarcane workers at risk for Mesoamerican nephropathy. Scandinavian Journal of Work, Environment and Health, 2021, 47, 377-386.	1.7	4
23	Epidemiology and Outcomes of COVID-19 in Home Dialysis Patients Compared with In-Center Dialysis Patients. Journal of the American Society of Nephrology: JASN, 2021, 32, 1569-1573.	3.0	25
24	Nephrologist Performance in the Merit-Based Incentive Payment System. Kidney Medicine, 2021, 3, 816-826.e1.	1.0	8
25	Value-Based Care in Nephrology: The Kidney Care Choices Model and Other Reforms. Kidney360, 2021, 2, 1677-1683.	0.9	20
26	Dialysis and Total Health Care Costs in the United States and Worldwide: The Financial Impact of a Single-Payer Dominant System in the US. Journal of the American Society of Nephrology: JASN, 2021, 32, 2137-2139.	3.0	6
27	GFR decline and prior dysuria among Nicaraguan sugarcane workers. ISEE Conference Abstracts, 2021, .	0.0	0
28	Safety and Efficacy of Tenapanor for Long-term Serum Phosphate Control in Maintenance Dialysis: A 52-Week Randomized Phase 3 Trial (PHREEDOM). Kidney360, 2021, 2, 1600-1610.	0.9	12
29	Immunogenicity of SARS-CoV-2 Vaccine in Dialysis. Journal of the American Society of Nephrology: JASN, 2021, 32, 2735-2742.	3.0	64
30	The ESRD Quality Incentive Program: Everything Can Be Improved. American Journal of Kidney Diseases, 2021, 78, 907-910.	2.1	8
31	Association of Urine Biomarkers of Kidney Tubule Injury and Dysfunction With Frailty Index and Cognitive Function in Persons With CKD in SPRINT. American Journal of Kidney Diseases, 2021, 78, 530-540.e1.	2.1	13
32	AJKD at 40: The Boston Era—Years 25-35 (2007-2016). American Journal of Kidney Diseases, 2021, 78, 475-476.	2.1	0
33	Perceptions of Telehealth vs In-Person Visits Among Older Adults With Advanced Kidney Disease, Care Partners, and Clinicians. JAMA Network Open, 2021, 4, e2137193.	2.8	65
34	Serum bicarbonate and cardiovascular events in hypertensive adults: results from the Systolic Blood Pressure Intervention Trial. Nephrology Dialysis Transplantation, 2020, 35, 1377-1384.	0.4	16
35	Assessing quality care in kidney disease: The double-edged sword versus the Gordian knot. Seminars in Dialysis, 2020, 33, 10-17.	0.7	4
36	COVID-19 Infection Risk Among Hemodialysis Patients in Long-term Care Facilities. Kidney Medicine, 2020, 2, 810-811.	1.0	8

#	ARTICLE	IF	CITATIONS
37	Trends in Mineral Metabolism Treatment Strategies in Patients Receiving Hemodialysis in the United States. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2020, 15, 1603-1613.	2.2	6
38	Factors Associated With Death in Critically Ill Patients With Coronavirus Disease 2019 in the US. <i>JAMA Internal Medicine</i> , 2020, 180, 1436.	2.6	711
39	Effects of Intensive Blood Pressure Control in Patients with and without Albuminuria. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2020, 15, 1121-1128.	2.2	15
40	Health Policy and Kidney Care in the United States: Core Curriculum 2020. <i>American Journal of Kidney Diseases</i> , 2020, 76, 720-730.	2.1	20
41	COVID-19 in dialysis patients: outlasting and outsmarting a pandemic. <i>Kidney International</i> , 2020, 98, 1402-1404.	2.6	36
42	Authors' Reply. <i>Journal of the American Society of Nephrology: JASN</i> , 2020, 31, 2966-2966.	3.0	1
43	Efficacy and Safety of Expanded Hemodialysis with the TheraNova 400 Dialyzer. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2020, 15, 1310-1319.	2.2	50
44	COVID-19 Universal Testing in Hemodialysis Facilities to Reduce Infection Risk. <i>Kidney Medicine</i> , 2020, 2, 681-683.	1.0	1
45	Effect of intensive versus standard blood pressure control on cerebral blood flow in SPRINT. <i>Alzheimer's and Dementia</i> , 2020, 16, e042155.	0.4	0
46	Vitamin K status, cardiovascular disease, and all-cause mortality: a participant-level meta-analysis of 3 US cohorts. <i>American Journal of Clinical Nutrition</i> , 2020, 111, 1170-1177.	2.2	23
47	Hemodialysis and COVID-19: An Achilles' Heel in the Pandemic Health Care Response in the United States. <i>Kidney Medicine</i> , 2020, 2, 227-230.	1.0	37
48	Evaluation of Screening Tests for Cognitive Impairment in Patients Receiving Maintenance Hemodialysis. <i>Journal of the American Society of Nephrology: JASN</i> , 2020, 31, 855-864.	3.0	41
49	Multidisciplinary Medication Therapy Management and Hospital Readmission in Patients Undergoing Maintenance Dialysis: A Retrospective Cohort Study. <i>American Journal of Kidney Diseases</i> , 2020, 76, 13-21.	2.1	22
50	Measuring Quality in Kidney Care: An Evaluation of Existing Quality Metrics and Approach to Facilitating Improvements in Care Delivery. <i>Journal of the American Society of Nephrology: JASN</i> , 2020, 31, 602-614.	3.0	28
51	Advance Care Planning Among Older Adults With Advanced Non-Dialysis-Dependent CKD and Their Care Partners: Perceptions Versus Reality?. <i>Kidney Medicine</i> , 2020, 2, 116-124.	1.0	15
52	Long-term Clinical Outcomes Among Responders and Nonresponders to the In-Center Hemodialysis Consumer Assessment of Healthcare Providers and Systems (ICH CAHPS) Survey. <i>Kidney Medicine</i> , 2020, 2, 181-188.	1.0	4
53	Nomenclature for kidney function and disease: report of a Kidney Disease: Improving Global Outcomes (KDIGO) Consensus Conference. <i>Kidney International</i> , 2020, 97, 1117-1129.	2.6	407
54	Blood pressure and volume management in dialysis: conclusions from a Kidney Disease: Improving Global Outcomes (KDIGO) Controversies Conference. <i>Kidney International</i> , 2020, 97, 861-876.	2.6	126

#	ARTICLE	IF	CITATIONS
55	Kidney Disease, Intensive Hypertension Treatment, and Risk for Dementia and Mild Cognitive Impairment: The Systolic Blood Pressure Intervention Trial. <i>Journal of the American Society of Nephrology: JASN</i> , 2020, 31, 2122-2132.	3.0	25
56	Home Dialysis in the United States: To Increase Utilization, Address Disparities. <i>Kidney Medicine</i> , 2020, 2, 95-97.	1.0	6
57	Home Dialysis in the United States: A Roadmap for Increasing Peritoneal Dialysis Utilization. <i>American Journal of Kidney Diseases</i> , 2020, 75, 413-416.	2.1	26
58	High-Dose Versus Standard-Dose Influenza Vaccine in Hemodialysis Patients. <i>American Journal of Kidney Diseases</i> , 2020, 75, 456.	2.1	5
59	Heart failure management in dialysis patients: Many treatment options with no clear evidence. <i>Seminars in Dialysis</i> , 2020, 33, 198-208.	0.7	20
60	Kidney Function, Self-Reported Symptoms, and Urine Findings in Nicaraguan Sugarcane Workers. <i>Kidney360</i> , 2020, 1, 1042-1051.	0.9	4
61	Albuminuria and Allograft Failure, Cardiovascular Disease Events, and All-Cause Death in Stable Kidney Transplant Recipients: A Cohort Analysis of the FAVORIT Trial. <i>American Journal of Kidney Diseases</i> , 2019, 73, 51-61.	2.1	30
62	Association of Intensive vs Standard Blood Pressure Control With Cerebral White Matter Lesions. <i>JAMA - Journal of the American Medical Association</i> , 2019, 322, 524.	3.8	285
63	Cognitive Impairment in CKD: Pathophysiology, Management, and Prevention. <i>American Journal of Kidney Diseases</i> , 2019, 74, 782-790.	2.1	188
64	Transfers to Hemodialysis Among US Patients Initiating Renal Replacement Therapy With Peritoneal Dialysis. <i>American Journal of Kidney Diseases</i> , 2019, 74, 620-628.	2.1	34
65	Chronic kidney disease and valvular heart disease: conclusions from a Kidney Disease: Improving Global Outcomes (KDIGO) Controversies Conference. <i>Kidney International</i> , 2019, 96, 836-849.	2.6	80
66	Chronic Kidney Disease and Coronary Artery Disease. <i>Journal of the American College of Cardiology</i> , 2019, 74, 1823-1838.	1.2	403
67	Effect of Intensive vs Standard Blood Pressure Control on Probable Dementia. <i>JAMA - Journal of the American Medical Association</i> , 2019, 321, 553.	3.8	786
68	Kidney Transplantation in Lupus Nephritis: Can We Do Even Better?. <i>Annals of Internal Medicine</i> , 2019, 170, 266.	2.0	1
69	Blood Pressure, Chronic Kidney Disease Progression, and Kidney Allograft Failure in Kidney Transplant Recipients: A Secondary Analysis of the FAVORIT Trial. <i>American Journal of Hypertension</i> , 2019, 32, 816-823.	1.0	8
70	Kidney Medicine: What's in a Name?. <i>Kidney Medicine</i> , 2019, 1, 1-2.	1.0	0
71	Blood Pressure and Cognitive Decline in Prevalent Hemodialysis Patients. <i>American Journal of Nephrology</i> , 2019, 49, 460-469.	1.4	10
72	KDOQI US Commentary on the 2017 ACC/AHA Hypertension Guideline. <i>American Journal of Kidney Diseases</i> , 2019, 73, 437-458.	2.1	24

#	ARTICLE	IF	CITATIONS
73	Dialysis initiation, modality choice, access, and prescription: conclusions from a Kidney Disease: Improving Global Outcomes (KDIGO) Controversies Conference. <i>Kidney International</i> , 2019, 96, 37-47.	2.6	235
74	Oral nutritional supplements and 30-day readmission rate in hypoalbuminemic maintenance hemodialysis patients. <i>Hemodialysis International</i> , 2019, 23, 93-100.	0.4	11
75	Value-Based Kidney Care: Aligning Metrics and Incentives to Improve the Health of People with Kidney Disease. <i>Journal of the American Society of Nephrology: JASN</i> , 2019, 30, 2282-2284.	3.0	3
76	Readmissions Metrics in Hemodialysis: Do the Specifics Matter?. <i>Journal of the American Society of Nephrology: JASN</i> , 2019, 30, 184-186.	3.0	2
77	Safety and cardiovascular efficacy of spironolactone in dialysis-dependent ESRD (SPin-D): a randomized, placebo-controlled, multiple dosage trial. <i>Kidney International</i> , 2019, 95, 973-982.	2.6	70
78	Cardiovascular Disease in Chronic Kidney Disease. , 2019, , 176-193.e9.		0
79	Hyperuricemia, Acute and Chronic Kidney Disease, Hypertension, and Cardiovascular Disease: Report of a Scientific Workshop Organized by the National Kidney Foundation. <i>American Journal of Kidney Diseases</i> , 2018, 71, 851-865.	2.1	362
80	Discussing Conservative Management With Older Patients With CKD: An Interview Study of Nephrologists. <i>American Journal of Kidney Diseases</i> , 2018, 71, 627-635.	2.1	87
81	Serum Uromodulin: A Biomarker of Long-Term Kidney Allograft Failure. <i>American Journal of Nephrology</i> , 2018, 47, 275-282.	1.4	31
82	“End-of-Life Care? I’m not Going to Worry About That Yet.” Health Literacy Gaps and End-of-Life Planning Among Elderly Dialysis Patients. <i>Gerontologist</i> , The, 2018, 58, 290-299.	2.3	65
83	Left Ventricular Assist Devices, Kidney Disease, and Dialysis. <i>American Journal of Kidney Diseases</i> , 2018, 71, 257-266.	2.1	35
84	Hemodialysis patient characteristics associated with better experience as measured by the In-center Hemodialysis Consumer Assessment of Healthcare Providers and Systems (ICH CAHPS) survey. <i>BMC Nephrology</i> , 2018, 19, 340.	0.8	9
85	Pulse wave velocity and central aortic pressure in systolic blood pressure intervention trial participants. <i>PLoS ONE</i> , 2018, 13, e0203305.	1.1	14
86	The Affordable Care Act, Kidney Transplant Access, and Kidney Disease Care in the United States. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2018, 13, 982-983.	2.2	3
87	Acute Kidney Injury in Sugarcane Workers at Risk for Mesoamerican Nephropathy. <i>American Journal of Kidney Diseases</i> , 2018, 72, 475-482.	2.1	62
88	Telehealth and Home Dialysis. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2018, 13, 1288-1290.	2.2	29
89	Characterizing Approaches to Dialysis Decision Making with Older Adults. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2018, 13, 1188-1196.	2.2	47
90	Medicare Advantage Ratings And Voluntary Disenrollment Among Patients With End-Stage Renal Disease. <i>Health Affairs</i> , 2018, 37, 70-77.	2.5	31

#	ARTICLE	IF	CITATIONS
91	Smoking and outcomes in kidney transplant recipients: a post hoc survival analysis of the FAVORIT trial. <i>International Journal of Nephrology and Renovascular Disease</i> , 2018, Volume 11, 155-164.	0.8	20
92	Engagement in decision-making and patient satisfaction: a qualitative study of older patients' perceptions of dialysis initiation and modality decisions. <i>Nephrology Dialysis Transplantation</i> , 2017, 32, gfw307.	0.4	60
93	B-Type Natriuretic Peptide and Cardiac Troponin I Are Associated With Adverse Outcomes in Stable Kidney Transplant Recipients. <i>Transplantation</i> , 2017, 101, 182-190.	0.5	10
94	Dialysate Composition for Hemodialysis: Changes and Changing Risk. <i>Seminars in Dialysis</i> , 2017, 30, 112-120.	0.7	23
95	Cognitive Decline and Its Risk Factors in Prevalent Hemodialysis Patients. <i>American Journal of Kidney Diseases</i> , 2017, 69, 780-787.	2.1	76
96	<i>Leptospira</i> seropositivity as a risk factor for Mesoamerican Nephropathy. <i>International Journal of Occupational and Environmental Health</i> , 2017, 23, 1-10.	1.2	39
97	Blood Pressure Management in Hemodialysis Patients: What We Know And What Questions Remain. <i>Seminars in Dialysis</i> , 2017, 30, 203-212.	0.7	19
98	Serum Phosphorus and Risk of Cardiovascular Disease, All-Cause Mortality, or Graft Failure in Kidney Transplant Recipients: An Ancillary Study of the FAVORIT Trial Cohort. <i>American Journal of Kidney Diseases</i> , 2017, 70, 377-385.	2.1	23
99	Cognitive Function and Kidney Disease: Baseline Data From the Systolic Blood Pressure Intervention Trial (SPRINT). <i>American Journal of Kidney Diseases</i> , 2017, 70, 357-367.	2.1	60
100	The ESRD Quality Incentive Program—Can We Bridge the Chasm?. <i>Journal of the American Society of Nephrology: JASN</i> , 2017, 28, 1697-1706.	3.0	49
101	Circulating Vitamin K Is Inversely Associated with Incident Cardiovascular Disease Risk among Those Treated for Hypertension in the Health, Aging, and Body Composition Study (Health ABC). <i>Journal of Nutrition</i> , 2017, 147, 888-895.	1.3	43
102	Urine Fibrosis Markers and Risk of Allograft Failure in Kidney Transplant Recipients: A Case-Cohort Ancillary Study of the FAVORIT Trial. <i>American Journal of Kidney Diseases</i> , 2017, 69, 410-419.	2.1	49
103	Effect of Intensive Blood-Pressure Treatment on Patient-Reported Outcomes. <i>New England Journal of Medicine</i> , 2017, 377, 733-744.	13.9	160
104	KDOQI US Commentary on the 2017 KDIGO Clinical Practice Guideline Update for the Diagnosis, Evaluation, Prevention, and Treatment of Chronic Kidney Disease—Mineral and Bone Disorder (CKD-MBD). <i>American Journal of Kidney Diseases</i> , 2017, 70, 737-751.	2.1	257
105	Toward Establishing Core Outcome Domains For Trials in Kidney Transplantation. <i>Transplantation</i> , 2017, 101, 1887-1896.	0.5	83
106	Vascular imaging for hemodialysis vascular access planning. <i>Hemodialysis International</i> , 2017, 21, 490-497.	0.4	4
107	Establishing Core Outcome Domains in Hemodialysis: Report of the Standardized Outcomes in Nephrology—Hemodialysis (SONG-HD) Consensus Workshop. <i>American Journal of Kidney Diseases</i> , 2017, 69, 97-107.	2.1	148
108	Dialysate Potassium, Serum Potassium, Mortality, and Arrhythmia Events in Hemodialysis: Results From the Dialysis Outcomes and Practice Patterns Study (DOPPS). <i>American Journal of Kidney Diseases</i> , 2017, 69, 266-277.	2.1	123

#	ARTICLE	IF	CITATIONS
109	Does an Aspirin a Day Keep the Doctor Away?. American Journal of Kidney Diseases, 2017, 69, 337-340.	2.1	2
110	[P2â€“013]: Bâ€“VITAMIN THERAPY LOWERS HOMOCYSTEINE AND IMPROVES SELECTIVE COGNITIVE OUTCOMES IN THE RANDOMIZED FAVORIT ANCILLARY COGNITIVE TRIAL. Alzheimer's and Dementia, 2017, 13, P609.	0.4	0
111	White matter damage in maintenance hemodialysis patients: a diffusion tensor imaging study. BMC Nephrology, 2017, 18, 213.	0.8	36
112	Fluid First or Not So Fast: Ultrafiltration Rate and the ESRD Quality Incentive Program. Clinical Journal of the American Society of Nephrology: CJASN, 2016, 11, 1330-1332.	2.2	5
113	Risk of renal cell carcinoma following exposure to metalworking fluids among autoworkers. Occupational and Environmental Medicine, 2016, 73, 656-662.	1.3	5
114	Ten Years Atop the Masthead. American Journal of Kidney Diseases, 2016, 68, 825-827.	2.1	2
115	Characterization of Mesoamerican Nephropathy in a Kidney Failure Hotspot in Nicaragua. American Journal of Kidney Diseases, 2016, 68, 716-725.	2.1	47
116	Ultrafiltration Rate Thresholds in Maintenance Hemodialysis: An NKF-KDOQI Controversies Report. American Journal of Kidney Diseases, 2016, 68, 522-532.	2.1	27
117	Peripherally Inserted Central Catheters and Hemodialysis Outcomes. Clinical Journal of the American Society of Nephrology: CJASN, 2016, 11, 1434-1440.	2.2	29
118	Comparison of Prescribed and Measured Dialysate Sodium: A Quality Improvement Project. American Journal of Kidney Diseases, 2016, 67, 439-445.	2.1	27
119	Peripherally Inserted Central Catheters (PICCs) in CKD: PICCâ€™ing the Best Access for Kidney Disease Patients. American Journal of Kidney Diseases, 2016, 67, 724-727.	2.1	5
120	Chronic kidney disease, cerebral blood flow, and white matter volume in hypertensive adults. Neurology, 2016, 86, 1208-1216.	1.5	48
121	Nephrologist-Facilitated Advance Care Planning for Hemodialysis Patients: A Quality Improvement Project. American Journal of Kidney Diseases, 2016, 68, 103-109.	2.1	40
122	Aspirin Use and Incident Cardiovascular Disease, Kidney Failure, and Death in Stable Kidney Transplant Recipients: A Post Hoc Analysis of the Folic Acid for Vascular Outcome Reduction in Transplantation (FAVORIT) Trial. American Journal of Kidney Diseases, 2016, 68, 277-286.	2.1	19
123	Ergocalciferol Supplementation in Hemodialysis Patients With Vitamin D Deficiency: A Randomized Clinical Trial. Journal of the American Society of Nephrology: JASN, 2016, 27, 1801-1810.	3.0	56
124	Urine Injury Biomarkers and Risk of Adverse Outcomes in Recipients of Prevalent Kidney Transplants: The Folic Acid for Vascular Outcome Reduction in Transplantation Trial. Journal of the American Society of Nephrology: JASN, 2016, 27, 2109-2121.	3.0	24
125	Biomarkers of Kidney Injury Among Nicaraguan Sugarcane Workers. American Journal of Kidney Diseases, 2016, 67, 209-217.	2.1	97
126	Urine biomarkers of kidney injury among adolescents in Nicaragua, a region affected by an epidemic of chronic kidney disease of unknown aetiology. Nephrology Dialysis Transplantation, 2016, 31, 424-432.	0.4	56

#	ARTICLE	IF	CITATIONS
127	Epidemiology of End-Stage Renal Disease. , 2016, , 3-13.		5
128	Estimation of Life-Years Saved by Solid-Organ Transplant. JAMA Surgery, 2015, 150, 1015.	2.2	6
129	Nutrition, vitamin D, and health outcomes in hemodialysis. Current Opinion in Nephrology and Hypertension, 2015, 24, 546-556.	1.0	6
130	In Reply to "More Evidence Needed Before Lower Dialysate Sodium Concentrations Can Be Recommended". American Journal of Kidney Diseases, 2015, 65, 520.	2.1	7
131	Changes in kidney function among Nicaraguan sugarcane workers. International Journal of Occupational and Environmental Health, 2015, 21, 241-250.	1.2	103
132	Better Informing Older Patients With Kidney Failure in an Era of Patient-Centered Care. American Journal of Kidney Diseases, 2015, 65, 372-374.	2.1	9
133	The Phosphate Binder Ferric Citrate and Mineral Metabolism and Inflammatory Markers in Maintenance Dialysis Patients: Results From Prespecified Analyses of a Randomized Clinical Trial. American Journal of Kidney Diseases, 2015, 66, 479-488.	2.1	41
134	KDOQI Clinical Practice Guideline for Hemodialysis Adequacy: 2015 Update. American Journal of Kidney Diseases, 2015, 66, 884-930.	2.1	822
135	Stroke and Chronic Kidney Disease: Epidemiology, Pathogenesis, and Management Across Kidney Disease Stages. Seminars in Nephrology, 2015, 35, 311-322.	0.6	71
136	Vascular Access Choice in Incident Hemodialysis Patients. Journal of the American Society of Nephrology: JASN, 2015, 26, 183-191.	3.0	110
137	Cognitive Function and All-Cause Mortality in Maintenance Hemodialysis Patients. American Journal of Kidney Diseases, 2015, 65, 303-311.	2.1	95
138	Cognitive Performance before and during Hemodialysis: A Randomized Cross-Over Trial. Nephron Clinical Practice, 2014, 124, 151-158.	2.3	26
139	Exercise to Improve Physical Function and Quality of Life in CKD. Clinical Journal of the American Society of Nephrology: CJASN, 2014, 9, 2023-2024.	2.2	9
140	Cognitive impairment in chronic kidney disease: keep vascular disease in mind. Kidney International, 2014, 85, 505-507.	2.6	53
141	<sc>FGF</sc> and cognitive performance in hemodialysis patients. Hemodialysis International, 2014, 18, 78-86.	0.4	37
142	BP, Cardiovascular Disease, and Death in the Folic Acid for Vascular Outcome Reduction in Transplantation Trial. Journal of the American Society of Nephrology: JASN, 2014, 25, 1554-1562.	3.0	60
143	Reduced speed of microvascular blood flow in hemodialysis patients versus healthy controls: a coherent hemodynamics spectroscopy study. Journal of Biomedical Optics, 2014, 19, 026005.	1.4	25
144	Asymmetric Dimethylarginine, Race, and Mortality in Hemodialysis Patients. Clinical Journal of the American Society of Nephrology: CJASN, 2014, 9, 1426-1433.	2.2	15

#	ARTICLE	IF	CITATIONS
145	Depression and All-Cause Mortality in Hemodialysis Patients. American Journal of Nephrology, 2014, 40, 12-18.	1.4	54
146	Allopurinol as a Kidney-Protective, Cardioprotective, and Antihypertensive Agent: Hype or Reality?. Blood Purification, 2014, 37, 172-178.	0.9	9
147	Cognitive and physical function in chronic kidney disease. Current Opinion in Nephrology and Hypertension, 2014, 23, 291-297.	1.0	48
148	Cardiac Function and Cardiovascular Disease in Chronic Kidney Disease. , 2014, , 488-496.		1
149	Commentary on "The DOPPS Practice Monitor for US Dialysis Care: Potential Impact of Recent Guidelines and Regulatory Changes on Management of Mineral and Bone Disorder Among US Hemodialysis Patients": The Calm Before the 2016 Storm?. American Journal of Kidney Diseases, 2014, 63, 854-858.	2.1	1
150	Improving Clinical Outcomes Among Hemodialysis Patients: A Proposal for a "Volume First" Approach From the Chief Medical Officers of US Dialysis Providers. American Journal of Kidney Diseases, 2014, 64, 685-695.	2.1	131
151	A Palliative Approach to Dialysis Care. Clinical Journal of the American Society of Nephrology: CJASN, 2014, 9, 2203-2209.	2.2	120
152	Oral Intradialytic Nutritional Supplement Use and Mortality in Hemodialysis Patients. American Journal of Kidney Diseases, 2014, 63, 276-285.	2.1	85
153	In Reply to "Etiological Versus Prognostic Models in Cohort Studies" and "Nutritional Supplement Use in Hemodialysis Patients". American Journal of Kidney Diseases, 2014, 63, 1068.	2.1	14
154	Measures of blood pressure and cognition in dialysis patients. Hemodialysis International, 2013, 17, 24-31.	0.4	7
155	Anatomic Brain Disease in Hemodialysis Patients: A Cross-sectional Study. American Journal of Kidney Diseases, 2013, 61, 271-278.	2.1	103
156	Chronic kidney disease in Nicaragua: a qualitative analysis of semi-structured interviews with physicians and pharmacists. BMC Public Health, 2013, 13, 350.	1.2	53
157	Cognitive Impairment in Dialysis Patients: Focus on the Blood Vessels?. American Journal of Kidney Diseases, 2013, 61, 187-190.	2.1	31
158	Commentary on "The DOPPS Practice Monitor for US Dialysis Care: Trends Through December 2011": Results From Year One. American Journal of Kidney Diseases, 2013, 61, 346-348.	2.1	1
159	What can we learn from the U.S. expanded end-stage renal disease bundle?. Health Policy, 2013, 110, 164-171.	1.4	28
160	Changes in Anthropometry and Mortality in Maintenance Hemodialysis Patients in the HEMO Study. American Journal of Kidney Diseases, 2013, 62, 1141-1150.	2.1	38
161	Commentary on "The DOPPS Practice Monitor for US Dialysis Care: Update on Trends in Anemia Management 2 Years Into the Bundle": Iron(y) Abounds 2 Years Later. American Journal of Kidney Diseases, 2013, 62, 1217-1220.	2.1	7
162	Low 25-Hydroxyvitamin D Levels and Cognitive Impairment in Hemodialysis Patients. Clinical Journal of the American Society of Nephrology: CJASN, 2013, 8, 979-986.	2.2	29

#	ARTICLE	IF	CITATIONS
163	The Central American Epidemic of CKD. Clinical Journal of the American Society of Nephrology: CJASN, 2013, 8, 504-511.	2.2	91
164	Frequency of and risk factors for poor cognitive performance in hemodialysis patients. Neurology, 2013, 80, 471-480.	1.5	186
165	Kidney Disease and Cardiovascular Risk. JAMA - Journal of the American Medical Association, 2013, 310, 697.	3.8	0
166	Prevention and Management of Cardiovascular Disease in Kidney Disease and Kidney Failure. , 2013, , 123-135.		0
167	Association of sleep disturbances with cognitive impairment and depression in maintenance hemodialysis patients. Journal of Nephrology, 2013, 26, 101-110.	0.9	22
168	Comparing Mandated Health Care Reforms. Clinical Journal of the American Society of Nephrology: CJASN, 2012, 7, 1535-1543.	2.2	31
169	Critical and Honest Conversations. Clinical Journal of the American Society of Nephrology: CJASN, 2012, 7, 1664-1672.	2.2	157
170	Cognitive Dysfunction and Depression in Adult Kidney Transplant Recipients: Baseline Findings from the FAVORIT Ancillary Cognitive Trial (FACT). , 2012, 22, 268-276.e3.		30
171	The Kidney Disease Quality of Life Cognitive Function Subscale and Cognitive Performance in Maintenance Hemodialysis Patients. American Journal of Kidney Diseases, 2012, 60, 417-426.	2.1	45
172	A Decade After the KDOQI CKD Guidelines: Impact on the Cardiovascular Diseaseâ€œCKD Paradigm. American Journal of Kidney Diseases, 2012, 60, 710-712.	2.1	15
173	Lipid-Lowering Therapy in Individuals With CKD: Lessons Learned From SHARP. American Journal of Kidney Diseases, 2012, 59, 170-173.	2.1	7
174	Commentary on â€œThe DOPPS Practice Monitor for US Dialysis Care: Trends Through August 2011': An ESA Confluence. American Journal of Kidney Diseases, 2012, 60, 165-167.	2.1	6
175	Oral Nutritional Supplement Use in Dialysis Patients: Full Speed Ahead?. American Journal of Kidney Diseases, 2012, 60, 507-509.	2.1	4
176	Staying Put, But Not Standing Still. American Journal of Kidney Diseases, 2012, 59, 1-3.	2.1	136
177	Commentary on â€œThe DOPPS Practice Monitor for US Dialysis Care: Trends Through April 2011â€™: No Surprises Yet. American Journal of Kidney Diseases, 2012, 59, 312-314.	2.1	1
178	Kidney Function and Risk of Cardiovascular Disease and Mortality in Kidney Transplant Recipients: The FAVORIT Trial. American Journal of Transplantation, 2012, 12, 2437-2445.	2.6	103
179	A Review of the Costs and Cost Effectiveness of Interventions in Chronic Kidney Disease. Pharmacoeconomics, 2011, 29, 839-861.	1.7	32
180	Timing Hemodialysis Initiation: A Call for Clinical Judgment. American Journal of Kidney Diseases, 2011, 57, 562-565.	2.1	11

#	ARTICLE	IF	CITATIONS
181	The 2011 ESRD Prospective Payment System: Welcome to the Bundle. American Journal of Kidney Diseases, 2011, 57, 539-541.	2.1	9
182	Cardiovascular Disease and Cognitive Function in Maintenance Hemodialysis Patients. American Journal of Kidney Diseases, 2011, 58, 773-781.	2.1	95
183	Transvenous Cardiac Device Wires and Vascular Access in Hemodialysis Patients. American Journal of Kidney Diseases, 2011, 58, 494-496.	2.1	40
184	Kidney function, albuminuria and age-related macular degeneration in NHANES III. Nephrology Dialysis Transplantation, 2011, 26, 3159-3165.	0.4	40
185	Prevalence of and risk factors for chronic kidney disease in rural Nicaragua. Nephrology Dialysis Transplantation, 2011, 26, 2798-2805.	0.4	114
186	Medicare Reimbursement Policies and Hemodialysis Vascular Access Outcomes: A Need for Change: Table 1.. Journal of the American Society of Nephrology: JASN, 2011, 22, 426-430.	3.0	31
187	Cognitive Function and Dialysis Adequacy: No Clear Relationship. American Journal of Nephrology, 2011, 33, 33-38.	1.4	45
188	Anemia Management in Chronic Kidney Disease: Bursting the Hemoglobin Bubble. Annals of Internal Medicine, 2010, 153, 53.	2.0	8
189	Risk Factors for ESRD: Lessons From a Community Study and Implications for Public Health. American Journal of Kidney Diseases, 2010, 55, 5-7.	2.1	3
190	The 2009 Proposed Rule for Prospective ESRD Payment: Historical Perspectives and Public Policiesâ€”Bundle Up!. American Journal of Kidney Diseases, 2010, 55, 217-222.	2.1	12
191	A New Forum for Brief Research Reports in AJKD. American Journal of Kidney Diseases, 2010, 55, 975-976.	2.1	1
192	Depression and Cognitive Function in Maintenance Hemodialysis Patients. American Journal of Kidney Diseases, 2010, 56, 704-712.	2.1	112
193	Uric Acid, CKD, and Cardiovascular Disease: Confounders, Culprits, and Circles. American Journal of Kidney Diseases, 2010, 56, 247-250.	2.1	32
194	Nadir Hemoglobin Levels after Discontinuation of Epoetin in Hemodialysis Patients. Clinical Journal of the American Society of Nephrology: CJASN, 2010, 5, 1621-1627.	2.2	3
195	Cardiovascular Disease in Patients with Chronic Kidney Disease. , 2010, , 128-144.		1
196	Chronic Kidney Disease and End-Stage Renal Disease in the Elderly Population: Current Prevalence, Future Projections, and Clinical Significance. Advances in Chronic Kidney Disease, 2010, 17, 293-301.	0.6	204
197	Chronic Kidney Disease Associated With Environmental Toxins and Exposures. Advances in Chronic Kidney Disease, 2010, 17, 254-264.	0.6	186
198	Kidney function and the risk of cardiovascular disease. BMJ: British Medical Journal, 2009, 338, b1307-b1307.	2.4	3

#	ARTICLE	IF	CITATIONS
199	Albuminuria, Cognitive Functioning, and White Matter Hyperintensities in Homebound Elders. American Journal of Kidney Diseases, 2009, 53, 438-447.	2.1	141
200	Computerized Decision Support for EPO Dosing in Hemodialysis Patients. American Journal of Kidney Diseases, 2009, 54, 1081-1088.	2.1	35
201	CKD classification based on estimated GFR over three years and subsequent cardiac and mortality outcomes: a cohort study. BMC Nephrology, 2009, 10, 26.	0.8	32
202	Public Health Consequences of Chronic Kidney Disease. Clinical Pharmacology and Therapeutics, 2009, 86, 566-569.	2.3	67
203	Cardiac Function and Cardiovascular Disease in Chronic Kidney Disease. , 2009, , 499-505.		0
204	The Relationship Between Nontraditional Risk Factors and Outcomes in Individuals With Stage 3 to 4 CKD. American Journal of Kidney Diseases, 2008, 51, 212-223.	2.1	131
205	Waist-to-Hip Ratio, Body Mass Index, and Subsequent Kidney Disease and Death. American Journal of Kidney Diseases, 2008, 52, 29-38.	2.1	224
206	Waist-to-Hip Ratio and Body Mass Index as Risk Factors for Cardiovascular Events in CKD. American Journal of Kidney Diseases, 2008, 52, 49-57.	2.1	133
207	The Cognition-Kidney Disease Connection: Lessons From Population-Based Studies in the United States. American Journal of Kidney Diseases, 2008, 52, 201-204.	2.1	19
208	Uric Acid and Incident Kidney Disease in the Community. Journal of the American Society of Nephrology: JASN, 2008, 19, 1204-1211.	3.0	387
209	Inflammation and cardiovascular events in individuals with and without chronic kidney disease. Kidney International, 2008, 73, 1406-1412.	2.6	42
210	Lowest Systolic Blood Pressure Is Associated with Stroke in Stages 3 to 4 Chronic Kidney Disease. Journal of the American Society of Nephrology: JASN, 2007, 18, 960-966.	3.0	93
211	Reducing versus Discontinuing Erythropoietin at High Hemoglobin Levels. Journal of the American Society of Nephrology: JASN, 2007, 18, 3184-3191.	3.0	16
212	Cardiovascular Disease and Subsequent Kidney Disease. Archives of Internal Medicine, 2007, 167, 1130.	4.3	201
213	Kidney Disease, Framingham Risk Scores, and Cardiac and Mortality Outcomes. American Journal of Medicine, 2007, 120, 552.e1-552.e8.	0.6	42
214	The Framingham Predictive Instrument in Chronic Kidney Disease. Journal of the American College of Cardiology, 2007, 50, 217-224.	1.2	285
215	Causes and Consequences of Chronic Kidney Disease: Implications for Managed Health Care. Journal of Managed Care Pharmacy, 2007, 13, 1-9.	2.2	46
216	Chronic kidney disease and cardiovascular disease: A bi-directional relationship?. Dialysis and Transplantation, 2007, 36, 113-120.	0.2	3

#	ARTICLE	IF	CITATIONS
217	Subcortical cognitive impairment in dialysis patients. Hemodialysis International, 2007, 11, 309-314.	0.4	78
218	Anemia as a Risk Factor for Kidney Function Decline in Individuals With Heart Failure—This study was presented in abstract form at the American Society of Nephrology meetings in 2005.. American Journal of Cardiology, 2007, 99, 1137-1142.	0.7	43
219	The Challenges of the Next 5 Years. American Journal of Kidney Diseases, 2007, 49, 1-2.	2.1	151
220	In the Literature: Cognitive Impairment in Hemodialysis Patients. American Journal of Kidney Diseases, 2007, 49, 183-185.	2.1	3
221	Dialysis Facility Ownership and Epoetin Dosing in Hemodialysis Patients: An Overview. American Journal of Kidney Diseases, 2007, 50, 349-353.	2.1	3
222	Cardiovascular Outcomes and All-Cause Mortality: Exploring the Interaction Between CKD and Cardiovascular Disease. American Journal of Kidney Diseases, 2006, 48, 392-401.	2.1	265
223	Cognitive function in dialysis patients. American Journal of Kidney Diseases, 2005, 45, 448-462.	2.1	154
224	Cardiovascular Disease in Patients with Chronic Kidney Disease. , 2005, , 158-173.		0
225	Effects of Anemia and Left Ventricular Hypertrophy on Cardiovascular Disease in Patients with Chronic Kidney Disease. Journal of the American Society of Nephrology: JASN, 2005, 16, 1803-1810.	3.0	180
226	Anemia as a Risk Factor for Cardiovascular Disease and All-Cause Mortality in Diabetes: The Impact of Chronic Kidney Disease. Journal of the American Society of Nephrology: JASN, 2005, 16, 3403-3410.	3.0	272
227	Chronic Kidney Disease as a Risk Factor for Cardiovascular Disease and All-Cause Mortality: A Pooled Analysis of Community-Based Studies. Journal of the American Society of Nephrology: JASN, 2004, 15, 1307-1315.	3.0	1,072
228	Managing dyslipidemia in chronic kidney disease. Journal of General Internal Medicine, 2004, 19, 1045-1052.	1.3	70
229	Kidney disease as a risk factor for recurrent cardiovascular disease and mortality. American Journal of Kidney Diseases, 2004, 44, 198-206.	2.1	243
230	Hematocrit and left ventricular mass: the Framingham Heart study. Journal of the American College of Cardiology, 2004, 43, 1276-1282.	1.2	45
231	Microalbuminuria: a marker of cardiovascular risk. American Journal of Kidney Diseases, 2003, 42, 596-598.	2.1	10
232	A 50-Year-Old Man with Chest Pain. American Journal of the Medical Sciences, 2003, 325, 70-74.	0.4	0